Subsequently, preclinical studies have revealed that BTK inhibition by ibrutinib overcomes resistance to lapatinib in HER2 BC by avoiding activation of the AKT signaling pathway by NRG or EGF [178]. This evidence concerns the gene AKT1 and breast cancer.